NCT00132808View on ClinicalTrials.gov

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

581

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Osteopenia
Interventions
DRUG

Zoledronic Acid

Zoledronic acid 5 mg intravenous

DRUG

Placebo

Physiologic 0.9% normal saline

Trial Locations (1)

07936

For information regarding facilities, please contact the Central Contact, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY